The Company reviews goodwill for potential impairment on at least an annual basis or more often if events so require. The Company performed its annual fair value impairment testing for fiscal 2026 and fiscal 2025 on May 1, 2026 (Successor) and May 4, 2025 (Predecessor), respectively.

Based on the results of the annual goodwill impairment test performed for the Company’s Behavioral and Clinical reporting units, which held 81.0% and 19.0% of the Company’s goodwill as of May 1, 2026 (Successor), respectively, the Company concluded that no goodwill impairment existed as of May 1, 2026 (Successor). However, the Company identified its Behavioral reporting unit as being at risk for impairment, as the estimated fair value of this reporting unit exceeded its respective carrying value by less than 10% as of May 1, 2026 (Successor).

The Company also conducted an interim goodwill impairment test for its Behavioral and Clinical reporting units during the three months ended March 31, 2026 (Successor) because various qualitative and quantitative factors collectively indicated a triggering event had occurred. Based on the results of the interim impairment test, the Company concluded that no goodwill impairment existed as of March 31, 2026 (Successor).

In performing the annual goodwill impairment test as of May 4, 2025 (Predecessor), the Company determined that the carrying values of its goodwill reporting units did not exceed their respective fair values and, therefore, no impairment existed.

The Company also conducted an interim goodwill impairment test for its Behavioral and Clinical reporting units during the three months ended March 29, 2025 (Predecessor) because various qualitative and quantitative factors collectively indicated a triggering event had occurred. Based on the results of the interim impairment test, the Company concluded that no goodwill impairment existed as of March 29, 2025 (Predecessor).

The components of other intangible assets, net as of June 30, 2026 (Successor) and December 31, 2025 (Successor) were as follows:


	Successor
	June 30,
	2026
		Gross				Net
	Useful	Carrying		Accumulated		Carrying
	Life	Value		Amortization		Value
Indefinite-lived intangible asset:
Trade name	Indefinite	$	320,000	$	—	$	320,000
Finite-lived intangible assets:
Database	3 years		46,000		15,585		30,415
Developed technology	3-6 years		70,000		19,821		50,179
Customers/subscribers	1 year		58,000		58,000		—
Customer relationships	6 years		35,000		5,929		29,071
Capitalized software and website development costs	3 years		26,768		3,144		23,624
Total other intangible assets		$	555,768	$	102,479	$	453,289


	Successor
	December 31,
	2025
		Gross				Net
	Useful	Carrying		Accumulated		Carrying
	Life	Value		Amortization		Value
Indefinite-lived intangible asset:
Trade name	Indefinite	$	320,000	$	—	$	320,000
Finite-lived intangible assets:
Database	3 years		46,000		7,982		38,018
Developed technology	3-6 years		70,000		10,151		59,849
Customers/subscribers	1 year		58,000		30,192		27,808
Customer relationships	6 years		35,000		3,036		31,964
Capitalized software and website development costs	3 years		13,552		527		13,025
Total other intangible assets		$	542,552	$	51,888	$	490,664

Aggregate amortization expense for finite-lived intangible assets was recorded in the amounts of $25,325 and $50,591 for the three and six months ended June 30, 2026 (Successor), respectively. Aggregate amortization expense for finite-lived intangible assets was recorded in the amounts of $1,623, $6,455 and $12,405 for the period from June 25, 2025 through June 30, 2025 (Successor), the period from March 30, 2025 through June 24, 2025 (Predecessor) and the period from December 29, 2024 through June 24, 2025 (Predecessor), respectively.

The Company reviews other indefinite-lived intangible assets for potential impairment on at least an annual basis or more often if events so require. As discussed above, the Company performed its annual fair value impairment testing for fiscal 2026 and fiscal 2025 on May 1, 2026 (Successor) and May 4, 2025 (Predecessor), respectively.

Based on the results of the annual impairment test performed for the Company’s trade name indefinite-lived intangible asset, the Company concluded that no impairment existed as of May 1, 2026 (Successor). However, the Company identified its trade name indefinite-lived intangible asset as being at risk for impairment, as the estimated fair value of this asset exceeded its respective carrying value by less than 10% as of May 1, 2026 (Successor).

As discussed above, based on the triggering event indicated during the three months ended March 31, 2026 (Successor), the Company performed an interim impairment test for its trade name indefinite-lived intangible asset. Based on the results of the interim impairment test, the Company concluded that no impairment existed as of March 31, 2026 (Successor).

In performing the annual impairment test as of May 4, 2025 (Predecessor) for the Company’s franchise rights acquired indefinite-lived intangible asset, the Company determined that the carrying value did not exceed its respective fair value and, therefore, no impairment existed.

As discussed above, based on the triggering event indicated during the three months ended March 29, 2025 (Predecessor), the Company performed an interim impairment test for its franchise rights acquired indefinite-lived intangible asset. Based on the results of the interim impairment test, the Company determined that the carrying value of its United States indefinite-lived franchise rights acquired unit of account, which held 100.0% of the Company’s indefinite-lived franchise rights acquired at the March 29, 2025 (Predecessor) balance sheet date, exceeded its fair value. Accordingly, the Company recorded an impairment charge for its United States unit of account of $27,549 in the first quarter of fiscal 2025 (Predecessor). The impairment charge recorded in the first quarter of fiscal 2025 (Predecessor) was driven primarily by the weighted average cost of capital used in the interim impairment tests, reflecting market factors, including higher interest rates and the trading values of the Company’s equity and debt, and, to a lesser extent, business performance in the Behavioral business.